Material Event Form 8 K

Item 8.01 Other Events.

On November 25, 2024, Virpax Pharmaceuticals, Inc. (the "Company") received a letter from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the independent director and audit committee requirements for continued listing on the Nasdaq Capital Market, as set forth in Listing Rules 5605(b)(1) and 5605(c)(2) (the "Rules").

As previously disclosed in the Company's Form 8-K filed on November 22, 2024, the Company had appointed Ms. Esha Randhawa as an independent director and a member of the audit committee. This appointment remedied the deficiencies resulting from the resignation of Dr. Eric Floyd on September 20, 2024, which had caused the Company to fall out of compliance with the Rules.

Nasdaq has confirmed that, as of November 25, 2024, the Company has regained compliance with the Rules, and the matter is now closed.

The Company remains committed to maintaining compliance with all applicable Nasdaq listing standards.